<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943540</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 08.07</org_study_id>
    <nct_id>NCT00943540</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients</brief_title>
  <acronym>PRADA</acronym>
  <official_title>Pharmacokinetic and Safety Pilotstudy of RAltegravir and Atazanavir in a Once DAily Dose Regimen in HIV-1 Infected Patients (PRADA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The licensed dose of raltegravir is 400 mg twice daily with or without food. Raltegravir is&#xD;
      metabolized predominantly through glucuronidation by UGT1A1. Atazanavir increases the plasma&#xD;
      concentrations of raltegravir 400 mg twice daily by 72% due to inhibition of UGT 1A1.&#xD;
&#xD;
      This suggests that combined use of atazanavir and a lower dose frequency of raltegravir, once&#xD;
      daily for example, is possible. Another reason why raltegravir most likely can be applied is&#xD;
      that its pharmacodynamic effect is not related to Cmin but to AUC which is expected to be&#xD;
      similar for an 800mg QD dose when compared to 400mg BD. Phase III clinical trials evaluating&#xD;
      QD dosing of raltegravir are currently ongoing and interim results are expected to be&#xD;
      published in mid 2009.&#xD;
&#xD;
      A regimen of atazanavir and raltegravir in combination with lamivudine or emtricitabine may&#xD;
      be a well tolerated and effective NNRTI-, and ritonavir-sparing regimen that could be an&#xD;
      attractive option for both first and second line (after NRTI/NNRTI failure) treatment&#xD;
      regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics of raltegravir</measure>
    <time_frame>after two weeks of reference treatment and after two weeks of test treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>after two weeks treatment with the reference treatment and after two weeks treatment with the test treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>entire trial</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV Infection</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir BID-QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 1-4&#xD;
600 mg of atazanavir to be taken once daily&#xD;
400 mg of raltegravir to be taken twice daily&#xD;
300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily&#xD;
Week 5-8&#xD;
600 mg of atazanavir to be taken once daily&#xD;
800 mg of raltegravir to be taken once daily&#xD;
300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir QD</intervention_name>
    <description>Raltegravir 800mg QD</description>
    <arm_group_label>Raltegravir BID-QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir</intervention_name>
    <description>atazanavir</description>
    <arm_group_label>Raltegravir BID-QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine (or emtricitabine)</intervention_name>
    <description>lamivudine (or emtricitabine)</description>
    <arm_group_label>Raltegravir BID-QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-infected as documented by positive HIV antibody test and confirmed by Western&#xD;
             Blot.&#xD;
&#xD;
          -  Subject is at least 18 years of age at the day of screening.&#xD;
&#xD;
          -  Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations.&#xD;
&#xD;
          -  HIV-1 RNA &lt; 40 copies/mL for at least 6 months on antiretroviral therapy.&#xD;
&#xD;
          -  Subject has no history of previous virological failure or documented resistance&#xD;
             mutations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of sensitivity/idiosyncrasy to the drug or chemically related compounds or&#xD;
             excipients, which may be employed in the trial.&#xD;
&#xD;
          -  Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          -  Inability to understand the nature and extent of the trial and the procedures&#xD;
             required.&#xD;
&#xD;
          -  Pregnant female (as confirmed by an HCG test performed less than 3 weeks before the&#xD;
             first dose) or breast-feeding female.&#xD;
&#xD;
          -  Abnormal serum transaminases determined as levels being &gt; 5 times upper limit of&#xD;
             normal (see Appendix A for normal ranges of clinical laboratory values).&#xD;
&#xD;
          -  Concomitant use of medications that interfere with raltegravir or atazanavir&#xD;
             pharmacokinetics: rifampicin, irinotecan, midazolam, triazolam, ergotamine,&#xD;
             dihydroergotamine, cisapride, pimozide, lovastatin, simvastatin, indinavir, proton&#xD;
             pump inhibitors, H2 receptor antagonists, St. john's wort, Ginkgo Biloba, didanosine,&#xD;
             tenofovir, efavirenz, nevirapine, antacids, clarithromycin, phenytoin, phenobarbital,&#xD;
             carbamazepine.&#xD;
&#xD;
          -  Active hepatobiliary or hepatic disease (including chronic hepatitis B infection).&#xD;
&#xD;
          -  Alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Burger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital Arnhem</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Jansen A, Colbers EP, van der Ven AJ, Richter C, Rockstroh JK, Wasmuth JC, van Luin M, Burger DM. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients. HIV Med. 2013 Aug;14(7):449-52. doi: 10.1111/hiv.12029. Epub 2013 Mar 18.</citation>
    <PMID>23506243</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <name_title>D.M. Burger, PhD, PharmD</name_title>
    <organization>Radboud University Medical Centre Nijmegen</organization>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>single dose</keyword>
  <keyword>raltegravir</keyword>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

